Company intelligence / Profile preview
Agastiya Biotech
Bonsall, California, United Statesagastiyabiotech.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
AB-001, their lead drug candidate, is currently in Phase 2 clinical trials for multiple cancer indications. It has shown promising results in Phase 1 studies for metastatic solid tumors with a novel immunotherapy mechanism that selectively destroys tumors without harming healthy cells. The FDA has awarded Orphan Drug Designations for Glioblastoma, Pancreatic and Acute Myeloid Leukemia indications for AB001.
- Therapeutic areas
- Infectious DiseasesDermatologyEndocrinologyOncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Vopec Pharmaceuticals
Beyond the preview
Go deeper on Agastiya Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Agastiya Biotech.